Our Alzheimer's drug was not a complete bust, says vTv; Xtalpi raises $46M more for AI drug discovery engine
→ Still recovering from the hammering it took on the failure of its Alzheimer’s drug, little vTv $VTVT is pushing out post hoc analysis on a tiny subgroup of patients in an effort to prove its drug isn’t worthless. A tiny group of 18 Alzheimer’s patients with diabetes demonstrated a 6.1 point benefit on ADAS-cog relative to the placebo group. They claimed that was statistically significant, though skeptics are likely to hoot.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.